Assessing ANI Pharmaceuticals (ANIP) Valuation After Mixed Share Performance And Cortrophin Gel Growth Prospects
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
ANI Pharmaceuticals (ANIP) has been drawing investor attention after a period of mixed share performance, with the stock showing small moves over the past month but a sharper decline across the past 3 months.
See our latest analysis for ANI Pharmaceuticals.
At a share price of $82.99, ANI Pharmaceuticals has recently seen weaker short term share price momentum, including a 1-day share price return of 2.81% decline and a 90-day share price return of 11.94% decline, yet its 1-year total shareholder return of 41.52% and 5-year total shareholder return of 190.78% show that longer term holders have so far been rewarded.
If you are comparing ANI with other drug makers, this could be a good moment to broaden your watchlist and check out pharma stocks with solid dividends as another pocket of opportunity in the sector.
With revenue of $826.88m, net income of $34.148m and a last close of $82.99, the big question now is whether ANI Pharmaceuticals is still trading at a discount or if the market is already pricing in future growth.
At a last close of $82.99 versus a narrative fair value of $109.25, ANI Pharmaceuticals is framed as materially undervalued, with that view hinging on a detailed revenue and margin story.
There is significant, untapped growth potential for Cortrophin Gel across core and emerging indications (neurology, nephrology, rheumatology, pulmonology, ophthalmology, and gout), with patient populations far below prior peaks and epidemiological data suggesting the addressable market could be several times larger due to an aging population and the rising prevalence of chronic diseases supporting multiyear revenue expansion.
Curious how this Cortrophin Gel runway, rare disease mix shift, and complex generics pipeline translate into that fair value and future profit multiple? The narrative ties together revenue expansion, margin change, and valuation assumptions in a way the current share price does not fully reflect. If you want to see the exact growth, margin, and earnings profile that this story is built on, the full narrative lays those numbers out clearly.
Result: Fair Value of $109.25 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this story could change quickly if payers clamp down on Cortrophin Gel reimbursement or if key generics lose exclusivity faster than expected.
